Nordic Nanovector begins Phase 1b trial of Betalutin and Rituximab combo for follicular lymphoma
Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of ... Read More
Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed ... Read More